Insider Buying: Biodesix, Inc. (NASDAQ:BDSX) Chairman Acquires $60,210.98 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Chairman John Patience acquired 9,497 shares of the company’s stock in a transaction on Thursday, November 18th. The shares were bought at an average price of $6.34 per share, for a total transaction of $60,210.98. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:BDSX opened at $6.73 on Thursday. The business has a 50 day moving average of $7.78 and a 200 day moving average of $10.33. The company has a market capitalization of $181.85 million and a price-to-earnings ratio of -5.06. Biodesix, Inc. has a 1-year low of $5.73 and a 1-year high of $31.99.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Monday, November 15th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. During the same period in the prior year, the company posted ($31.93) earnings per share. On average, research analysts anticipate that Biodesix, Inc. will post -1.64 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in Biodesix by 258.8% in the second quarter. BlackRock Inc. now owns 573,734 shares of the company’s stock worth $7,579,000 after purchasing an additional 413,826 shares during the period. Cannell Peter B & Co. Inc. purchased a new stake in shares of Biodesix in the second quarter worth $2,716,000. Kornitzer Capital Management Inc. KS grew its stake in shares of Biodesix by 34.3% in the second quarter. Kornitzer Capital Management Inc. KS now owns 437,530 shares of the company’s stock worth $5,780,000 after acquiring an additional 111,690 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Biodesix in the second quarter worth $1,321,000. Finally, Vanguard Group Inc. grew its stake in shares of Biodesix by 35.7% in the second quarter. Vanguard Group Inc. now owns 364,135 shares of the company’s stock worth $4,810,000 after acquiring an additional 95,757 shares during the last quarter. Institutional investors own 18.99% of the company’s stock.

A number of equities research analysts recently issued reports on BDSX shares. Zacks Investment Research cut Biodesix from a “hold” rating to a “sell” rating in a research note on Wednesday, October 20th. BTIG Research cut their price objective on Biodesix from $28.00 to $22.00 and set a “buy” rating for the company in a report on Thursday, September 23rd. Morgan Stanley lowered Biodesix from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $21.00 to $11.00 in a report on Wednesday, November 17th. Finally, Canaccord Genuity cut their price objective on Biodesix from $24.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, November 16th.

About Biodesix

Biodesix, Inc operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions.

Featured Article: What does it mean to hold a stock in street name?

Insider Buying and Selling by Quarter for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.